NCT00392353 - Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

November 22, 2006

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Acute Erythroid LeukemiaAcute Megakaryoblastic LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaMyelodysplastic SyndromeMyelodysplastic Syndrome With Excess BlastsMyelodysplastic Syndrome With Ring SideroblastsRecurrent Adult Acute Myeloid LeukemiaRefractory Anemia

Interventions

DRUG

Azacitidine

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Vorinostat

Given PO

Trial Locations (7)

10029

Mount Sinai Hospital, New York

10065

NYP/Weill Cornell Medical Center, New York

10461

Montefiore Medical Center-Weiler Hospital, The Bronx

10467

Montefiore Medical Center - Moses Campus, The Bronx

11030

North Shore University Hospital, Manhasset

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

60637

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH